Business Context and Reporting Period
Company: QT Imaging Holdings, Inc. (QTI/QTIH)
Reporting Period: Fiscal Year Ended December 31, 2024
Business Overview: A medical device company developing and commercializing the QT Breast Scanner, a non-ionizing, 3D ultrasound imaging system for breast cancer screening and diagnosis. The company operates as a single segment focused on the QT Breast Scanner and future product candidates (orthopedic and infant scanners).
Listing Status: Delisted from Nasdaq on January 28, 2025, due to failure to meet market value and minimum bid price requirements. Trading resumed on the OTCQB Venture Market under symbol "QTIH" on March 11, 2025.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $4.88 million | $0.04 million |
| Cost of Revenue | $2.24 million | $0.13 million |
| Gross Profit | $2.64 million | ($0.09 million) |
| Operating Expenses | $14.82 million | $4.91 million |
| Net Loss | ($8.98 million) | ($6.10 million) |
| Cash Used in Operating Activities | ($10.03 million) | ($2.65 million) |
| Cash and Restricted Cash (End of Period) | $1.19 million | $0.18 million |
| Accumulated Deficit | ($31.94 million) | ($17.77 million) |
Debt & Liquidity: As of December 31, 2024, the company had a working capital deficit of $4.9 million. Significant debt obligations included the Yorkville Note and Cable Car Note, which were subsequently settled in February 2025 via a new $10.1 million term loan from Lynrock Lake Master Fund LP.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by $4.84 million (Not Meaningful % change) driven by the sale of 11 QT Breast Scanners in 2024 compared to zero in 2023.
- Expense Surge: Operating expenses increased by $9.9 million (202% increase). Selling, General, and Administrative (SG&A) expenses rose $8.1 million, primarily due to $3.9 million in non-recurring transaction expenses related to the Business Combination and increased professional services.
- Non-Cash Gains: The company recorded significant non-cash gains from changes in fair value of liabilities: $4.82 million from derivative liability, $3.23 million from earnout liability, and $0.19 million from warrant liability, driven by the decline in the company's stock price.
- Capital Structure: The company completed a Business Combination in March 2024. Subsequent to year-end, it secured a $10.1 million senior secured term loan to repay existing debt and fund working capital.
Guidance, Outlook, and Risks
Management Commentary & Strategy:
- Commercialization: The company relies on an exclusive distribution agreement with NXC Imaging for the U.S. market, which includes Minimum Order Quantities (MOQs) projecting potential cash inflows of $18.0 million in 2025 and $27.0 million in 2026.
- Manufacturing: Entered into a manufacturing agreement with Canon Medical Systems Corporation (CMSC) in March 2025 to scale production of the QT Breast Scanner.
- Product Pipeline: Developing an Open Partial Angle Scanner for orthopedic and infant imaging markets.
Key Risks & Contingencies:
- Liquidity: The company has a history of net losses and negative cash flows. Continued operations depend on achieving revenue targets from distribution agreements and securing additional financing.
- Regulatory: The QT Breast Scanner is currently cleared as an adjunct to mammography, not a replacement. Future revenue growth depends on obtaining FDA clearance for primary screening and securing insurance reimbursement codes.
- Delisting: Trading on the OTCQB market may reduce liquidity, analyst coverage, and the ability to raise capital compared to Nasdaq listing.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting related to technical accounting and segregation of duties, though remediation efforts are underway.
Investor Verification Checklist
- Debt Settlement: Verify the terms and covenants of the February 2025 Lynrock Lake Term Loan ($10.1M) and the associated warrants issued to Lynrock Lake and Yorkville.
- Distribution Agreement: Confirm the enforceability and binding nature of the Minimum Order Quantities (MOQs) in the Amended Distribution Agreement with NXC Imaging.
- Manufacturing Capacity: Assess the progress of the Canon Medical Systems Corporation (CMSC) manufacturing agreement and the timeline for scaling production.
- Regulatory Pathway: Monitor the status of FDA submissions for primary screening clearance and the development of specific CPT billing codes for reimbursement.
- Stock Liquidity: Evaluate the impact of OTCQB trading on share price volatility and the ability of institutional investors to hold the stock.